The A-Mab Case Study shouts “QbD is here!” Yet, it is so complex and
“aspirational” that it almost needs a tour guide to navigate—project
facilitator John Berridge gets us started in the right direction.
Our editors' QbD blog offers analysis and commentary on developing better pharmaceuticals with better science and better business in mind. Reader comments welcome.
This webcast and panel discussion will focus on current best practices in energy management, including (but not limited to) the “low-hanging fruit,” with an eye towards practices that also help manufacturers cut costs.
OpEx and QbD, particularly the ideals of performance metrics and risk management, can be used to strengthen the relationship between partners in all pharmaceutical supply and contract situations. This webcast provides novel ideas and tangible suggestions for improving pharmaceutical partnerships.
With budgets rising and sales flattening, have we reached a tipping point? This paper by ATKearney outlines the choice that drug companies face—whether to play in ever-smaller niches or reassert their position as key partners in improving global healthcare outcomes—as well as how they can transform themselves.
A multi-article white paper from Oracle, including Accenture’s Henry Levy on enabling technology, Genzyme’s Jennifer Hunt on implementing a trial management system, and several leading consultants on clinical trials management of the future.
RSS
Create an Online Career Profile
Sign-up for Job Alerts
Utilize Career Resources
